Illumina to acquire Grail in deal worth $8bnChristian Fernsby ▼ | September 22, 2020
Illumina has signed a definitive agreement to acquire multi cancer blood test developer Grail for cash and stock consideration of $8bn.
Topics: Illumina Grail
Illumina currently owns 14.5% of Grail’s outstanding shares and approximately 12% on a fully diluted basis. Grail was established by Illumina in 2016 and became a spin-out later. The company specialises in the development of blood tests for the early detection of various cancer types. ■